These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

166 related items for PubMed ID: 29125233

  • 1. In vivo imaging xenograft models for the evaluation of anti-brain tumor efficacy of targeted drugs.
    Kita K, Arai S, Nishiyama A, Taniguchi H, Fukuda K, Wang R, Yamada T, Takeuchi S, Tange S, Tajima A, Nakada M, Yasumoto K, Motoo Y, Murakami T, Yano S.
    Cancer Med; 2017 Dec; 6(12):2972-2983. PubMed ID: 29125233
    [Abstract] [Full Text] [Related]

  • 2. Foretinib Overcomes Entrectinib Resistance Associated with the NTRK1 G667C Mutation in NTRK1 Fusion-Positive Tumor Cells in a Brain Metastasis Model.
    Nishiyama A, Yamada T, Kita K, Wang R, Arai S, Fukuda K, Tanimoto A, Takeuchi S, Tange S, Tajima A, Furuya N, Kinoshita T, Yano S.
    Clin Cancer Res; 2018 May 15; 24(10):2357-2369. PubMed ID: 29463555
    [Abstract] [Full Text] [Related]

  • 3. Combined therapy with mutant-selective EGFR inhibitor and Met kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant lung cancer.
    Nakagawa T, Takeuchi S, Yamada T, Nanjo S, Ishikawa D, Sano T, Kita K, Nakamura T, Matsumoto K, Suda K, Mitsudomi T, Sekido Y, Uenaka T, Yano S.
    Mol Cancer Ther; 2012 Oct 15; 11(10):2149-57. PubMed ID: 22844075
    [Abstract] [Full Text] [Related]

  • 4. Inhibition of EGFR and MEK surmounts entrectinib resistance in a brain metastasis model of NTRK1-rearranged tumor cells.
    Suzuki C, Nishiyama A, Arai S, Tange S, Tajima A, Tanimoto A, Fukuda K, Takumi Y, Kotani H, Takeuchi S, Yanagimura N, Ohtsubo K, Yamamoto N, Omori K, Yano S.
    Cancer Sci; 2022 Jul 15; 113(7):2323-2335. PubMed ID: 35363931
    [Abstract] [Full Text] [Related]

  • 5. MAN2A1-FER Fusion Gene Is Expressed by Human Liver and Other Tumor Types and Has Oncogenic Activity in Mice.
    Chen ZH, Yu YP, Tao J, Liu S, Tseng G, Nalesnik M, Hamilton R, Bhargava R, Nelson JB, Pennathur A, Monga SP, Luketich JD, Michalopoulos GK, Luo JH.
    Gastroenterology; 2017 Oct 15; 153(4):1120-1132.e15. PubMed ID: 28245430
    [Abstract] [Full Text] [Related]

  • 6. Discovery of Entrectinib: A New 3-Aminoindazole As a Potent Anaplastic Lymphoma Kinase (ALK), c-ros Oncogene 1 Kinase (ROS1), and Pan-Tropomyosin Receptor Kinases (Pan-TRKs) inhibitor.
    Menichincheri M, Ardini E, Magnaghi P, Avanzi N, Banfi P, Bossi R, Buffa L, Canevari G, Ceriani L, Colombo M, Corti L, Donati D, Fasolini M, Felder E, Fiorelli C, Fiorentini F, Galvani A, Isacchi A, Borgia AL, Marchionni C, Nesi M, Orrenius C, Panzeri A, Pesenti E, Rusconi L, Saccardo MB, Vanotti E, Perrone E, Orsini P.
    J Med Chem; 2016 Apr 14; 59(7):3392-408. PubMed ID: 27003761
    [Abstract] [Full Text] [Related]

  • 7. SKLB1206, a novel orally available multikinase inhibitor targeting EGFR activating and T790M mutants, ErbB2, ErbB4, and VEGFR2, displays potent antitumor activity both in vitro and in vivo.
    Pan Y, Xu Y, Feng S, Luo S, Zheng R, Yang J, Wang L, Zhong L, Yang HY, Wang BL, Yu Y, Liu J, Cao Z, Wang X, Ji P, Wang Z, Chen X, Zhang S, Wei YQ, Yang SY.
    Mol Cancer Ther; 2012 Apr 14; 11(4):952-62. PubMed ID: 22319204
    [Abstract] [Full Text] [Related]

  • 8. MET kinase inhibitor reverses resistance to entrectinib induced by hepatocyte growth factor in tumors with NTRK1 or ROS1 rearrangements.
    Takumi Y, Arai S, Suzuki C, Fukuda K, Nishiyama A, Takeuchi S, Sato H, Matsumoto K, Sugio K, Yano S.
    Cancer Med; 2023 Mar 14; 12(5):5809-5820. PubMed ID: 36416133
    [Abstract] [Full Text] [Related]

  • 9. Liposomal delivery of MicroRNA-7-expressing plasmid overcomes epidermal growth factor receptor tyrosine kinase inhibitor-resistance in lung cancer cells.
    Rai K, Takigawa N, Ito S, Kashihara H, Ichihara E, Yasuda T, Shimizu K, Tanimoto M, Kiura K.
    Mol Cancer Ther; 2011 Sep 14; 10(9):1720-7. PubMed ID: 21712475
    [Abstract] [Full Text] [Related]

  • 10. Inhibition of the T790M gatekeeper mutant of the epidermal growth factor receptor by EXEL-7647.
    Gendreau SB, Ventura R, Keast P, Laird AD, Yakes FM, Zhang W, Bentzien F, Cancilla B, Lutman J, Chu F, Jackman L, Shi Y, Yu P, Wang J, Aftab DT, Jaeger CT, Meyer SM, De Costa A, Engell K, Chen J, Martini JF, Joly AH.
    Clin Cancer Res; 2007 Jun 15; 13(12):3713-23. PubMed ID: 17575237
    [Abstract] [Full Text] [Related]

  • 11. In vivo imaging models of bone and brain metastases and pleural carcinomatosis with a novel human EML4-ALK lung cancer cell line.
    Nanjo S, Nakagawa T, Takeuchi S, Kita K, Fukuda K, Nakada M, Uehara H, Nishihara H, Hara E, Uramoto H, Tanaka F, Yano S.
    Cancer Sci; 2015 Mar 15; 106(3):244-52. PubMed ID: 25581823
    [Abstract] [Full Text] [Related]

  • 12. Paracrine activation of MET promotes peritoneal carcinomatosis in scirrhous gastric cancer.
    Zhao L, Yasumoto K, Kawashima A, Nakagawa T, Takeuchi S, Yamada T, Matsumoto K, Yonekura K, Yoshie O, Yano S.
    Cancer Sci; 2013 Dec 15; 104(12):1640-6. PubMed ID: 24118504
    [Abstract] [Full Text] [Related]

  • 13. Combining onartuzumab with erlotinib inhibits growth of non-small cell lung cancer with activating EGFR mutations and HGF overexpression.
    Sano Y, Hashimoto E, Nakatani N, Abe M, Satoh Y, Sakata K, Fujii T, Fujimoto-Ouchi K, Sugimoto M, Nagahashi S, Aoki M, Motegi H, Sasaki E, Yatabe Y.
    Mol Cancer Ther; 2015 Feb 15; 14(2):533-41. PubMed ID: 25522765
    [Abstract] [Full Text] [Related]

  • 14. Paracrine receptor activation by microenvironment triggers bypass survival signals and ALK inhibitor resistance in EML4-ALK lung cancer cells.
    Yamada T, Takeuchi S, Nakade J, Kita K, Nakagawa T, Nanjo S, Nakamura T, Matsumoto K, Soda M, Mano H, Uenaka T, Yano S.
    Clin Cancer Res; 2012 Jul 01; 18(13):3592-602. PubMed ID: 22553343
    [Abstract] [Full Text] [Related]

  • 15. The HGF inhibitory peptide HGP-1 displays promising in vitro and in vivo efficacy for targeted cancer therapy.
    Chen L, Li C, Zhu Y.
    Oncotarget; 2015 Oct 06; 6(30):30088-101. PubMed ID: 26254225
    [Abstract] [Full Text] [Related]

  • 16. Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications.
    Ardini E, Menichincheri M, Banfi P, Bosotti R, De Ponti C, Pulci R, Ballinari D, Ciomei M, Texido G, Degrassi A, Avanzi N, Amboldi N, Saccardo MB, Casero D, Orsini P, Bandiera T, Mologni L, Anderson D, Wei G, Harris J, Vernier JM, Li G, Felder E, Donati D, Isacchi A, Pesenti E, Magnaghi P, Galvani A.
    Mol Cancer Ther; 2016 Apr 06; 15(4):628-39. PubMed ID: 26939704
    [Abstract] [Full Text] [Related]

  • 17. Apatinib enhances antitumour activity of EGFR-TKIs in non-small cell lung cancer with EGFR-TKI resistance.
    Li F, Zhu T, Cao B, Wang J, Liang L.
    Eur J Cancer; 2017 Oct 06; 84():184-192. PubMed ID: 28822888
    [Abstract] [Full Text] [Related]

  • 18. Ferumoxytol and CpG oligodeoxynucleotide 2395 synergistically enhance antitumor activity of macrophages against NSCLC with EGFRL858R/T790M mutation.
    Wang G, Zhao J, Zhang M, Wang Q, Chen B, Hou Y, Lu K.
    Int J Nanomedicine; 2019 Oct 06; 14():4503-4515. PubMed ID: 31417255
    [Abstract] [Full Text] [Related]

  • 19. Met tyrosine kinase inhibitor, PF-2341066, suppresses growth and invasion of nasopharyngeal carcinoma.
    Zhao Y, Zhang J, Tian Y, Xue C, Hu Z, Zhang L.
    Drug Des Devel Ther; 2015 Oct 06; 9():4897-907. PubMed ID: 26345996
    [Abstract] [Full Text] [Related]

  • 20. Entrectinib is a potent inhibitor of Trk-driven neuroblastomas in a xenograft mouse model.
    Iyer R, Wehrmann L, Golden RL, Naraparaju K, Croucher JL, MacFarland SP, Guan P, Kolla V, Wei G, Cam N, Li G, Hornby Z, Brodeur GM.
    Cancer Lett; 2016 Mar 28; 372(2):179-86. PubMed ID: 26797418
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.